[
  {
    "ts": null,
    "headline": "What Do Analysts Think About Amgen Inc. (AMGN)?",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues. In […]",
    "url": "https://finnhub.io/api/news?id=ff2caeb5d7ed809402e75141b3932ff19b2b2f19b3dcf363b4edbb2ad8d11eee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758052704,
      "headline": "What Do Analysts Think About Amgen Inc. (AMGN)?",
      "id": 136782183,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the best drug stocks to buy right now. Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q2 2025 earnings on August 5, with total revenues increasing 9% to $9.2 billion compared to Q2 2024. GAAP earnings per share (EPS) rose 92% from $1.38 to $2.65, primarily attributed to higher revenues. In […]",
      "url": "https://finnhub.io/api/news?id=ff2caeb5d7ed809402e75141b3932ff19b2b2f19b3dcf363b4edbb2ad8d11eee"
    }
  },
  {
    "ts": null,
    "headline": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
    "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
    "url": "https://finnhub.io/api/news?id=7e39da9f066d83f8e6daf48c8f035e6212c064baab937ce0e5eb989930638999",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758045480,
      "headline": "AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?",
      "id": 136781283,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.",
      "url": "https://finnhub.io/api/news?id=7e39da9f066d83f8e6daf48c8f035e6212c064baab937ce0e5eb989930638999"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Insiders Sold US$12m Of Shares Suggesting Hesitancy",
    "summary": "Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...",
    "url": "https://finnhub.io/api/news?id=3486f02a4f803ff47995e68daacfde849702e84baa59eaddc98e1eec21289f1c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758034821,
      "headline": "Amgen Insiders Sold US$12m Of Shares Suggesting Hesitancy",
      "id": 136773495,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...",
      "url": "https://finnhub.io/api/news?id=3486f02a4f803ff47995e68daacfde849702e84baa59eaddc98e1eec21289f1c"
    }
  },
  {
    "ts": null,
    "headline": "Drug developer Dualitas launches $65 million funding round",
    "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
    "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024232,
      "headline": "Drug developer Dualitas launches $65 million funding round",
      "id": 136773229,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "(Reuters) -San Francisco-based biotech Dualitas Therapeutics said on Tuesday it has launched a $65 million early-stage funding round, and plans to use the proceeds to develop next-generation therapies for immunity-related diseases.  The series A funding round will be co-led by Versant Ventures and Qiming Venture Partners USA, with pharmaceutical major Eli Lilly also participating, Dualitas said.  The company did not disclose its valuation in the funding round.",
      "url": "https://finnhub.io/api/news?id=881acb8e3ec0da75c8685720d14818e1f016a46b756a1e6e7dcec442db9db8dd"
    }
  },
  {
    "ts": null,
    "headline": "Immuneering Appoints Dr. Thomas Schall as Chairman of the Board",
    "summary": "Thomas Schall Thomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder",
    "url": "https://finnhub.io/api/news?id=ba7ff9798fd86c8e492e9e1fe638aeaa44cb0cab5d53dc02a7c5c33a75ead17d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758024000,
      "headline": "Immuneering Appoints Dr. Thomas Schall as Chairman of the Board",
      "id": 136773497,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Thomas Schall Thomas Schall, Chariman of the Board of Directors of Immuneering NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the appointment of Thomas J. Schall, Ph.D., to Chairman of the Board of Directors. Dr. Schall is a renowned biotech executive and scientist with more than 30 years of leadership in drug discovery and development. He is best known as the founder",
      "url": "https://finnhub.io/api/news?id=ba7ff9798fd86c8e492e9e1fe638aeaa44cb0cab5d53dc02a7c5c33a75ead17d"
    }
  }
]